BioSimTM - ELISA Kits for BioSimilar Antibodies
Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. BioVision is pleased to offer one of the largest selections of ELISA Kits for detecting biosimilar antibodies and anti-drug antibodies in the research market. These ELISA Kits can be used to study dose-dependent pharmacokinetics, identify biomarkers for (non-)response, and risk factors for adverse drug reactions. Key Features:
BEST Seller!!!! BioSim™ Pembrolizumab (Keytruda®)(Human) ELISA Kit Pembrolizumab (Keytruda) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Pembrolizumab binds to the human cell surface receptor PD-1 (Programmed Cell Death Protein 1) and blocks its interaction with PD-L1, resulting in the activation of T-cell-mediated immune responses against tumor cells. Figure: Typical Standard Curve for BioSim™ Pembrolizumab (Keytruda®)(Human) ELISA Kit (Cat.No. E4383 ) Highlighted ELISA Kits for BioSimilar Antibodies and Anti-drug Antibodies:
Please click here to see BioVision's BioSimTM ELISA Kits for BioSimilar antibodies and check out our Biosimilar Antibodies and ELISA Kits mini brochure. |
DBA-ITALIA Srl
Via Umbria 10
20090 Segrate (Milano)
Tel. +39 02-26922300
Fax +39 02-26926058
Fax +39 02-26923535